Simplify Asset Management Inc. Acquires Shares of ADMA Biologics, Inc.

Simplify Asset Management Inc. has made a significant investment in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) during the fourth quarter of the previous year. According to its latest 13F filing with the Securities and Exchange Commission, the asset management firm purchased 385,188 shares of the biotechnology company, which are valued at around $6,606,000. This acquisition places ADMA Biologics as the 19th largest holding in Simplify Asset Management Inc.'s investment portfolio, constituting about 0.3% of the total portfolio.

Other Institutional Investments

Alongside Simplify, other institutional investors and hedge funds have also adjusted their positions in ADMA Biologics. For instance, the Healthcare of Ontario Pension Plan Trust Fund increased its stake by 13.9% in the third quarter of last year, acquiring an additional 80,400 shares for a total of 658,900 shares valued at approximately $13,171,000. Additionally, Lord Abbett & CO. LLC purchased a new stake worth about $61,858,000 in the same quarter. Raymond James Financial Inc. also joined in by acquiring a new stake valued at around $19,076,000 in the fourth quarter, while EWG Elevate Inc. made a smaller investment worth approximately $480,000 during the same period.

Market Ownership Overview

Citigroup Inc. has notably increased its position by 251.7% during the third quarter, now owning 387,226 shares valued at $7,741,000 after buying 277,138 additional shares. Currently, institutional investors and hedge funds own 75.68% of ADMA Biologics shares, highlighting the stock's appeal to larger investment entities.

Analyst Ratings and Performance

In terms of analyst outlook, Cantor Fitzgerald reaffirmed an "overweight" rating with a target price of $25.00 for ADMA Biologics shares in a research note released on March 4th.

ADMA Biologics Stock Performance

The share price of ADMA Biologics opened at $19.80 on the most recent trading day. The stock has a 50-day simple moving average of $16.76 and a two-hundred day simple moving average of $18.04. The company’s financial metrics indicate a debt-to-equity ratio of 0.48, a current ratio of 7.09, and a quick ratio of 3.26. Over the last year, ADMA Biologics has experienced a low of $5.90 and a high of $23.64, and its market capitalization stands at $4.68 billion, with a PE ratio of 70.71 and a beta of 0.60.

Company Overview

ADMA Biologics, Inc., a biopharmaceutical company, is actively involved in developing, manufacturing, and marketing specialty plasma-derived biologics. Its products are used in the treatment of immune deficiencies and infectious diseases, both in the United States and internationally. Some of its key offerings include BIVIGAM, an intravenous immune globulin (IVIG) product for primary humoral immunodeficiency, and ASCENIV, another IVIG product for similar indications. The company also offers Nabi-HB, which helps treat exposure to Hepatitis B.

investment, biotechnology, stocks